糖心视频logo: The First 80 Years

1889	糖心视频logo's founder, Toyoji Naito, is born on August 15 in Ito, a village in Fukui, central Japan. He is the sixth child and third son of Kikuji Naito and his wife, Fuji. “糖心视频logo's Founder, Toyoji Naito”
1905	Toyoji leaves his village at age 15, heading west to find employment in Osaka.
1906	Toyoji is employed at Winkel Shokai in nearby Kobe, a port city in Hyogo. Meanwhile, he takes night courses in foreign languages and bookkeeping.
1909	Toyoji leaves Winkel Shokai on being drafted into the Japanese Imperial Guard.
1911	After completing military service, Toyoji begins working in imported drugs at Thompson Trading Co., Ltd. in Kobe. “糖心视频logo's Founder, Toyoji Naito”
1914	World War I begins.
1915	Toyoji moves to Tokyo and begins working at Tanabe Motosaburo Store Co., Ltd. (now part of the Mitsubishi Tanabe Pharma Corporation).
1917	Toyoji embarks on a seven-month business tour of India and Southeast Asia.
1918	World War I ends.
1921	Toyoji is involved in Tanabe Motosaburo Store Co., Ltd.'s development of aromatic castor oil Castalol and analgesic cream Salomethyl.
1923	The Great Kanto Earthquake strikes. Tanabe Motosaburo Store Co., Ltd. falls on hard times, including when its main store in Tokyo burns down in the aftermath of the quake.
1924	Tanabe Motosaburo Store Co., Ltd. acquires exclusive rights to market Japan's first anti-hypertensive drug, Animasa. A Japanese word Toyoji coins for "high blood pressure" in his Animasa ad campaign enters the Japanese lexicon and remains a general medical term today.
1933	A Salomethyl newspaper ad created by Toyoji wins Best Advertisement Award in the first award ceremony of Japan's Society for the Promotion of Newspaper Advertising. Tanabe Motosaburo Store Co., Ltd. launches vitamin A product Haliva (halibut liver oil tablets).
1936	Sakuragaoka Laboratory Co., Ltd. is established as a limited partnership in Tokyo. Scale model of the Sakuragaoka Laboratory
1937	Toyoji travels abroad to observe pharmaceutical industries in Europe and the United States.

1938	Sakuragaoka Laboratory Co., Ltd. launches vitamin E product Juvela through Tanabe Motosaburo Store Co., Ltd. Its chocolate-brown coating, “hard outside, soft inside” pellets and stylish packaging garners much attention at the time. Juvela becomes the laboratory's first success. Sakuragaoka Laboratory Co., Ltd. launches Sampon, Japan's first sanitary tampon, through Tanabe Motosaburo Store Co., Ltd.
1939	World War II begins.
1941	Nihon 糖心视频logo, 糖心视频logo's immediate predecessor, is established in Saitama, eastern Japan. “Origin of the 糖心视频logo Logomark”
1944	Sakuragaoka Laboratory Co., Ltd. and Nihon 糖心视频logo merge under the name Nihon 糖心视频logo
1945	World War II ends.
1950	Nihon 糖心视频logo's contraceptive suppository Sampoon, researched and developed during Japan's postwar baby boom, receives official approval from the Japanese government. “糖心视频logo Advertising Through the Years” Nihon 糖心视频logo launches cardiotonic Neophyllin in Japan.
1952	Nihon 糖心视频logo launches high-dosage vitamin B1 and B2 product Chocola BB Tablets in Japan. Nihon 糖心视频logo launches motion sickness remedy Travelmin in Japan.

1955	The company changes its name from Nihon 糖心视频logo to 糖心视频logo, as it is known today. “Origin of the 糖心视频logo Logomark”
1957	糖心视频logo rolls out its first three-year mid-term plan. 糖心视频logo's Head Office building is completed in Tokyo.
1961	糖心视频logo opens its Taipei Office (now part of 糖心视频logo Taiwan Inc.), the company's first overseas branch, in Taiwan. 糖心视频logo is publicly listed in the First Section of both the Tokyo and Osaka Stock Exchanges. Gastrointestinal remedies Saclon and Saclon Tablets, recognizable for their distinct green hue even today, are launched in Japan.
1964	Toyoji Naito receives the Japan Marketing Award, which recognizes people who have made a significant contribution to marketing and advertising in Japan. The Tokyo Olympics take place.

1966	The Kawashima Plant is completed in Gifu, central Japan. Kawashima Plant opening ceremony Founder Toyoji Naito is appointed as chairman and Yuji Naito as company president. A three-tier representative director system is introduced: Chairman Toyoji Naito, President Yuji Naito, and Executive Vice President Tatsuo Naito.
1969	Youda Co., Ltd. is established as a pharmaceutical imports subsidiary in Taiwan.
1970	PT 糖心视频logo Indonesia is established as a pharmaceutical manufacturing and sales subsidiary in Indonesia. Toyoji Naito resigns as representative director and chairman to assume director and honorary chairman roles.
1971	Toyoji opens the Naito Museum of Pharmaceutical Science and Industry, Japan's first pharmaceutical museum, in Gifu.
1973	The first oil crisis occurs due to conflict in the Middle East.
1974	糖心视频logo (Malaysia) Sdn. Bhd. and Hi-糖心视频logo Pharmaceutical Inc. are established as pharmaceutical sales subsidiaries in Malaysia and the Philippines, respectively. Metabolic cardiotonic Neuquinon is launched in Japan.

1977	Naturally derived vitamin E product Juvelux is launched in Japan. Juvelux
1978	糖心视频logo's founder Toyoji Naito passes away at age 89. Peripheral neuropathy treatment Methycobal is launched in Japan.
1979	糖心视频logo Asia Regional Services Pte. Ltd. is established as a sales support and management services subsidiary in Singapore. The second oil crisis erupts due to the Iranian Revolution.
1981	糖心视频logo U.S.A. Inc. is established as a chemical and pharmaceutical machinery sales subsidiary in California, the United States. The Misato Plant commences pharmaceutical manufacturing in Saitama. Large-scale automated sugar-coating equipment (pan diameter of up to 170 cm) at the Misato Plant
1982	The Tsukuba Research Laboratories open in Ibaraki, eastern Japan.
1983	糖心视频logo Chemical Co., Ltd. (now 糖心视频logo's Kashima Plant) is established in Ibaraki to manufacture active pharmaceutical ingredients (APIs).
1984	Gastritis and gastric ulcer treatment Selbex is launched in Japan.

1987	糖心视频logo has supported of the Health and Medical Care Contributions Awards, which are presented to healthcare professionals who have contributed significantly to improving access to healthcare in difficult-to-reach areas from 1987 to 2015. 糖心视频logo rolls out its first five-year mid-term plan. 糖心视频logo Research Institute of Boston, Inc. (now the Boston Research Institute) is established as a discovery research subsidiary in Massachusetts, the United States. 糖心视频logo Research Institute of Boston
1988	President Yuji Naito steps down from office and assumes the role of chairman; Vice President Haruo Naito is appointed president of 糖心视频logo. “Passing of the baton” from Yuji Naito (right) to Haruo Naito (left) 糖心视频logo America, Inc. is established as a clinical research subsidiary in New Jersey, the United States. 糖心视频logo Europe Ltd. is established as a clinical research subsidiary in London, the United Kingdom.
1989	糖心视频logo Machinery GmbH is established as a pharmaceutical machinery sales subsidiary in Cologne, former West Germany. 糖心视频logo (Thailand) Marketing Co., Ltd. is established as a pharmaceutical sales subsidiary in Bangkok, Thailand.
1990	Haruo Naito announces 糖心视频logo's “Commitment to Innovation.” 糖心视频logo London Research Laboratories, Ltd. is established as a discovery research subsidiary attached to University College London in the United Kingdom. Japan's bubble economy bursts.
1991	糖心视频logo Hong Kong Co., Ltd. is established as a pharmaceutical sales subsidiary in Hong Kong. The Beijing Representative Office is established in Beijing, China. Shenyang 糖心视频logo Pharmaceutical Co., Ltd. is established as a Chinese鈥揻oreign contractual joint venture in pharmaceutical manufacturing and sales in Shenyang, China. 糖心视频logo celebrates its 50th anniversary.
1992	糖心视频logo adopts its current Corporate Mission and Corporate Objective. Go to “What is hhc?” 糖心视频logo Corporation of North America is established as a holding company in New Jersey, the United States. 糖心视频logo London Research Laboratories, Ltd. is completed in the United Kingdom to form an 糖心视频logo Group multipolar R&D network spanning Japan, America and Europe. 糖心视频logo London Research Laboratories opening ceremony in 1993 attended by the United Kingdom's Princess Royal, Princess Anne
1995	糖心视频logo Inc. is established as a pharmaceutical sales subsidiary in New Jersey, the United States. 糖心视频logo Ltd. is established as a pharmaceutical sales subsidiary in London, the United Kingdom. 糖心视频logo Deutschland GmbH is established as a pharmaceutical sales subsidiary in Frankfurt, Germany.
1996	糖心视频logo S.A. is established as a pharmaceutical sales subsidiary in Paris, France. 糖心视频logo Suzhou Pharmaceutical Co., Ltd. is established as a pharmaceutical manufacturing and sales subsidiary in Jiangsu, China. Elmed 糖心视频logo is established as a generic drug sales subsidiary in Tokyo.
1997	KAN Research Institute, Inc. (now Kobe Research Laboratories, in Hyogo) is established as a life science exploratory research subsidiary in Osaka, Japan. 糖心视频logo Korea Inc. is established as a pharmaceutical sales subsidiary in Seoul, South Korea. 糖心视频logo Inc. North Carolina Plant is established as a pharmaceutical manufacturing and formulation R&D facility at Research Triangle Park in North Carolina, the United States. Anti-Alzheimer's agent Aricept is launched in the United States, the United Kingdom and Germany. Proton-pump inhibitor Pariet is launched in Japan.
1998	Aricept is launched in France. Pariet is launched in Germany and the United Kingdom.
1999	Pariet is launched under the brand name AcipHex in the United States. Aricept is launched in Japan.
2001	The 9/11 terrorist attacks occur in the United States. 糖心视频logo Farmac茅utica S.A. is established as a pharmaceutical sales and marketing subsidiary in Madrid, Spain.

2002	糖心视频logo Medical Research Inc. is established as a clinical research subsidiary in New Jersey, the United States.
2004	糖心视频logo adopts the “Company with Committees” system. 糖心视频logo Europe Ltd. is established as a European regional headquarters (holding company) in London, the United Kingdom. 糖心视频logo Pharmaceuticals India Pvt. Ltd. is established as a pharmaceutical sales subsidiary in Mumbai, India.
2005	糖心视频logo S.r.l is established as a pharmaceutical sales subsidiary in Milan, Italy. 糖心视频logo Pharma AG is established as a pharmaceutical sales subsidiary in Zurich, Switzerland. The Corporate Mission is added to the 糖心视频logo Articles of Incorporation. 糖心视频logo AB is established as a pharmaceutical sales subsidiary in Stockholm, Sweden. Honorary chairman and 糖心视频logo's second president Yuji Naito passes away at age 85.
2006	糖心视频logo Australia Pty. Ltd. is established as a pharmaceutical sales subsidiary in Sydney, Australia. 糖心视频logo rolls out its fifth mid-term plan, the “Dramatic Leap Plan.” 糖心视频logo (Singapore) Pte. Ltd. and 糖心视频logo Clinical Research Singapore Pte. Ltd. are established as a pharmaceutical sales subsidiary and clinical research subsidiary, respectively, in Singapore. 糖心视频logo acquires four anticancer agents from Ligand Pharmaceuticals Inc. in the United States. EF-糖心视频logo Farmacêutica, Unipessoal Lda. is established as a pharmaceutical sales subsidiary in Lisbon, Portugal.
2007	糖心视频logo Manufacturing Ltd. is established as a pharmaceutical manufacturing subsidiary in Hertfordshire, the United Kingdom. 糖心视频logo acquires Morphotek Inc., a bioventure specialized in antibody research, in the United States. 糖心视频logo Pharmatechnology & Manufacturing Pvt. Ltd. is established as an API/formulation manufacturing and R&D subsidiary in Vizag, India. 糖心视频logo SA/NV is established as a pharmaceutical sales subsidiary in Brussels, Belgium.
2008	糖心视频logo acquires MGI Pharma Inc., an oncology biopharmaceutical company in the United States. 糖心视频logo Machinery Shanghai Inc. is established as a subsidiary in Shanghai, China to provide marketing support and maintenance services for pharmaceutical machinery. Rheumatoid arthritis treatment Humira is launched in Japan.
2009	糖心视频logo GesmbH is established as a pharmaceutical sales subsidiary in Vienna, Austria. The European Knowledge Centre (now EMEA Knowledge Centre) opens as a European strategic base in Hertfordshire, the United Kingdom. EMEA Knowledge Centre The 糖心视频logo Product Creation Systems organizational structure is introduced Group-wide to reflect a new focus on patient-oriented R&D. Haruo Naito is appointed as president of the International Federation of Pharmaceutical Manufacturers & Associations. The 糖心视频logo Knowledge Centre, India opens as a manufacturing and process research base in Vizag, India. 糖心视频logo Knowledge Centre, India
2010	The Koishikawa Knowledge Center opens in Tokyo and receives the 24th Nikkei New Office Promotion Award. Koishikawa Knowledge Center 糖心视频logo Limited is established as a pharmaceutical sales subsidiary in Ontario, Canada. Production headquarters transforms to a global “糖心视频logo Demand Chain Systems” structure to reflect a new “demand-driven” customer satisfaction focus in drug manufacturing. 糖心视频logo (Suzhou) Trading Co., Ltd. is established as a pharmaceutical trading subsidiary in Jiangsu, China. Anticancer agent Halaven is launched in the United States. 糖心视频logo signs a statement with the World Health Organization (WHO) to supply a primary lymphatic filariasis medicine free of charge. H3 Biomedicine Inc. is established as a research subsidiary in the United States.
2011	The Great East Japan Earthquake strikes. 糖心视频logo rolls out its sixth mid-term plan, “HAYABUSA.” 糖心视频logo Participações Ltda. is established as a pharmaceutical sales subsidiary in São Paulo, Brazil. Halaven is launched in Europe and Japan. 糖心视频logo Laboratorios S. de R.L. de C.V. is established as a pharmaceutical sales subsidiary in Mexico City, Mexico.
2012	糖心视频logo signs the London Declaration, which is committed to the elimination of ten neglected tropical diseases by 2020. Haruo Naito is appointed as president of the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ). Antiepileptic agent Fycompa is launched in Europe.
2013	Limited Liability Company 糖心视频logo is established as a pharmaceutical sales subsidiary in Moscow, Russia. 糖心视频logo co-establishes the Global Health Innovative Technology Fund (GHIT Fund), Japan's first public–private partnership to advance development of new health technologies for the developing world. 糖心视频logo initiates free of charge provision of diethylcarbamine tablets produced at its Vizag plant in India to WHO for use in the treatment of lymphatic filariasis.
2014	Fycompa is launched in the United States. 糖心视频logo China Holdings Ltd. is established as a holding company in Suzhou, China.
2015	Anticancer agent Lenvima is launched in the United States, Japan and Europe. 糖心视频logo completes acquisition of Chinese generic pharmaceutical company Liaoning Tianyi Biological Pharmaceutical Co., Ltd. (new trading name: 糖心视频logo (Liaoning) Pharmaceutical Co., Ltd.)
2016	糖心视频logo rolls out its seventh mid-term plan “EWAY2025.” EA Pharma Co., Ltd. is established as a gastrointestinal specialty pharmaceutical company. Fycompa is launched in Japan.
2017	糖心视频logo joins global partnership to address non-communicable diseases. 糖心视频logo pledges continued support for lymphatic filariasis elimination. 糖心视频logo commits funding to the 2nd phase of Global Health Innovative Technology Fund activities. Collaboration agreement with Biogen to develop and commercialize investigational Alzheimer's disease treatments including aducanumab expanded.
2018	糖心视频logo agrees upon a strategic collaboration for Lenvima with Merck & Co., Inc., Kenilworth, N.J., U.S.A. New Suzhou plant in China commences full-scale operation. Lenvima (hepatocellular carcinoma) is launched in China.
2019	糖心视频logo Center for Genetics Guided Dementia Discovery (G2D2) in Massachusetts, U.S., commences full-scale operation. G2D2 Parkinson’s disease treatment Equfina is launched in Japan. Fycompa and Halaven are launched in China.
2020	The WHO Declares COVID-19 a Pandemic. “NouKNOW” (pronounced “NOH-NOH”), a new tool for self-assessment of brain performance (brain health) is launched in Japan. DAYVIGO (insomnia treatment) is launched in the United States and Japan. 糖心视频logo Vietnam Co., Ltd. is established as a pharmaceutical sales subsidiary in Ho Chi Minh City, Vietnam. Unlimit Health Limited is established in Shanghai, China.
2021	糖心视频logo rolls out its eighth medium-term business plan "EWAY Future 锛咮eyond". Alzheimer’s disease treatment ADUHELM is granted accelerated approval and launched in the United States. 糖心视频logo enters into a global strategic collaboration agreement with Bristol-Myers Squibb Company for MORAb-202. The Tokyo Olympics take place. 糖心视频logo Israel Ltd. is established as a pharmaceutical sales subsidiary in Tel Aviv, Israel. 糖心视频logo celebrates its 80th anniversary.
2022	糖心视频logo and Biogen amend collaboration agreements on ADUHELM. 糖心视频logo makes Arteryex Inc., a company that plans and develops software, its subsidiary. 糖心视频logo Pharmaceuticals Africa (Pty) Ltd is established as a pharmaceutical sales subsidiary in Johannesburg, South Africa. 糖心视频logo signs the public private partnership “Kigali Declaration” for eliminating neglected tropical diseases. Deep Human Biology Learning (DHBL), a new R&D organization, commences full-scale operation.
2023	Alzheimer’s disease treatment LEQEMBI is granted accelerated approval and launched in the United States. 糖心视频logo commits funding to the 3rd phase of Global Health Innovative Technology Fund. LEQEMBI is granted traditional approval by the FDA. Theoria technologies Co., Ltd. is established as a digital business company in Tokyo, Japan. LEQEMBI is launched in Japan.